Promakhos Therapeutics Inc.
Somerville, MA
- UEI
- FQ4ND4Z1QCS4
- CAGE
- 905C8
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 66 Highland Ave #3, Somerville, MA 02143, USA
- Website
- promakhos.com
- Founded
- 2021
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Preclinical validation of small molecule immunomodulators for the treatment of crohn's disease | National Institute of Diabetes and Digestive and Kidney Diseases (NIH) | $543,730 |
Quick answers
Is Promakhos Therapeutics Inc. registered in SAM.gov?
Yes. Promakhos Therapeutics Inc.'s SAM.gov registration is active through February 26, 2027.
What is Promakhos Therapeutics Inc.'s most recent federal award?
Promakhos Therapeutics Inc.'s most recent federal grant award is Preclinical validation of small molecule immunomodulators for the treatment of crohn's disease (R43DK135153), from National Institute of Diabetes and Digestive and Kidney Diseases (NIH), on September 1, 2023.
On GovTribe
See Promakhos Therapeutics Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors